Compare FTFT & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | SILO |
|---|---|---|
| Founded | N/A | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Apparel |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.2M |
| IPO Year | 2008 | 2011 |
| Metric | FTFT | SILO |
|---|---|---|
| Price | $1.16 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 233.8K | ★ 1.4M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,829,805.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.56 | $0.22 |
| 52 Week High | $4.03 | $1.01 |
| Indicator | FTFT | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 43.78 |
| Support Level | $0.94 | $0.33 |
| Resistance Level | $1.32 | $0.42 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 9.97 | 17.62 |
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.